Abstract：
BACKGROUND: A large number of both preclinical and clinical studies demonstrates the efficiency of bioregulatory peptides for the treatment of prostatitis and chronic pelvic pain syndrome (CPPS). A relatively new drug in this group is Prostatex, the active ingredient of which is bovine prostate extract.
OBJECTIVE: To evaluate the effect of taking Prostatex on the intensity of CPPS, the sexual function, and the results of microscopy of expressed prostate secretions and urinalysis.
METHODS: A cohort of patients aged 25-65 years with chronic abacterial prostatitis and complaints of chronic pelvic pain was analyzed. The abacterial type of prostatitis was confirmed by bacteriological examination of expressed prostate secretions. The patients received Prostatex for 30 days according to the following scheme: 1 suppository rectally 1 time per day. The follow-up was 30 days. Before starting the drug and at the end of the 30-day course, patients completed the Chronic Prostatitis Symptom Index (NIH-CPSI) and the sexual function questionnaire. In addition, urinalysis and microscopic study of expressed prostate secretions was performed.
RESULTS: A total of 1700 patients were included in the study. While taking the drug, there was a significant decrease in pain during digital rectal examination, as well as in the intensity of pain as a symptom of CPPS. The severity of symptoms after treatment was lower in all domains of NIH-CPSI. Microscopic study of the expressed prostate secretions during treatment showed a decrease in the number of patients with excessive number of leukocytes. The sexual function improved, while urinalysis and microscopy of expressed prostate secretions returned to the reference values.
CONCLUSIONS: The use of Prostatex for the treatment of patients with CPPS reduces the severity of pain and other symptoms of chronic prostatitis, increases sexual function and normalizes the expressed prostate secretions and urinalysis. In order to obtain data of a higher level of evidence, it is necessary to carry out randomized, blind, placebo-controlled studies.
OBJECTIVE: To evaluate the effect of taking Prostatex on the intensity of CPPS, the sexual function, and the results of microscopy of expressed prostate secretions and urinalysis.
METHODS: A cohort of patients aged 25-65 years with chronic abacterial prostatitis and complaints of chronic pelvic pain was analyzed. The abacterial type of prostatitis was confirmed by bacteriological examination of expressed prostate secretions. The patients received Prostatex for 30 days according to the following scheme: 1 suppository rectally 1 time per day. The follow-up was 30 days. Before starting the drug and at the end of the 30-day course, patients completed the Chronic Prostatitis Symptom Index (NIH-CPSI) and the sexual function questionnaire. In addition, urinalysis and microscopic study of expressed prostate secretions was performed.
RESULTS: A total of 1700 patients were included in the study. While taking the drug, there was a significant decrease in pain during digital rectal examination, as well as in the intensity of pain as a symptom of CPPS. The severity of symptoms after treatment was lower in all domains of NIH-CPSI. Microscopic study of the expressed prostate secretions during treatment showed a decrease in the number of patients with excessive number of leukocytes. The sexual function improved, while urinalysis and microscopy of expressed prostate secretions returned to the reference values.
CONCLUSIONS: The use of Prostatex for the treatment of patients with CPPS reduces the severity of pain and other symptoms of chronic prostatitis, increases sexual function and normalizes the expressed prostate secretions and urinalysis. In order to obtain data of a higher level of evidence, it is necessary to carry out randomized, blind, placebo-controlled studies.
摘要：
背景：大量临床前和临床研究证明了生物调节肽治疗前列腺炎和慢性盆腔疼痛综合征（CPPS）的有效性。这一组中相对较新的药物是Prostatex，其中的活性成分是牛前列腺提取物。
目的：为了评估服用Prostatex对CPPS强度的影响，性功能,以及表达的前列腺分泌物和尿液分析的显微镜检查结果。
方法：对25-65岁慢性非细菌性前列腺炎和慢性盆腔疼痛主诉的患者进行队列分析。通过对前列腺分泌物的细菌学检查证实了前列腺炎的非细菌类型。根据以下方案，患者接受Prostatex治疗30天：1栓剂直肠1次/天。随访时间为30天。在开始药物之前和30天课程结束时，患者完成慢性前列腺炎症状指数(NIH-CPSI)和性功能问卷.此外,对前列腺分泌物的表达进行尿液分析和显微镜研究。
结果：共有1700名患者被纳入研究。服用药物时，直肠指检时疼痛明显减轻,以及作为CPPS症状的疼痛强度。在NIH-CPSI的所有领域中，治疗后症状的严重程度均较低。对治疗过程中前列腺分泌物表达的显微镜研究表明，白细胞过多的患者人数减少。性功能得到改善，而尿液分析和表达的前列腺分泌物的显微镜检查恢复到参考值。
结论：使用Prostatex治疗CPPS患者可降低慢性前列腺炎的疼痛和其他症状的严重程度，增加性功能并使表达的前列腺分泌物和尿液分析正常化。为了获得更高水平的证据数据，有必要进行随机化，盲,安慰剂对照研究。
目的：为了评估服用Prostatex对CPPS强度的影响，性功能,以及表达的前列腺分泌物和尿液分析的显微镜检查结果。
方法：对25-65岁慢性非细菌性前列腺炎和慢性盆腔疼痛主诉的患者进行队列分析。通过对前列腺分泌物的细菌学检查证实了前列腺炎的非细菌类型。根据以下方案，患者接受Prostatex治疗30天：1栓剂直肠1次/天。随访时间为30天。在开始药物之前和30天课程结束时，患者完成慢性前列腺炎症状指数(NIH-CPSI)和性功能问卷.此外,对前列腺分泌物的表达进行尿液分析和显微镜研究。
结果：共有1700名患者被纳入研究。服用药物时，直肠指检时疼痛明显减轻,以及作为CPPS症状的疼痛强度。在NIH-CPSI的所有领域中，治疗后症状的严重程度均较低。对治疗过程中前列腺分泌物表达的显微镜研究表明，白细胞过多的患者人数减少。性功能得到改善，而尿液分析和表达的前列腺分泌物的显微镜检查恢复到参考值。
结论：使用Prostatex治疗CPPS患者可降低慢性前列腺炎的疼痛和其他症状的严重程度，增加性功能并使表达的前列腺分泌物和尿液分析正常化。为了获得更高水平的证据数据，有必要进行随机化，盲,安慰剂对照研究。
